Pseudoceramide-containing physiological lipid mixture reduces adverse effects of topical steroids

Allergy, Asthma and Immunology Research

Volumn 3, Issue 2, 2011, Pages 96-102

  Kim, Hyun Jung ^a   Park, Hyun Jung ^b   Yun, Jae Nam ^b   Jeong, Se Kyoo ^b   Ahn, Sung Ku ^c   Lee, Seung Hun ^d  

^a Seoul Medical Center   (South Korea)

^b NeoPharm Co Ltd   (South Korea)

^c Yonsei University Wonju   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

Epidermal permeability barrier function; Multilamellar emulsion; Topical glucocorticoids

Indexed keywords

CHOLESTEROL; CYCLINE; FATTY ACID; GLUCOCORTICOID; HYDROCORTISONE; LIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; MALE; MOUSE; NONHUMAN; PERMEABILITY BARRIER; PH; SKIN ATROPHY; SKIN EDEMA; SKIN WATER LOSS; SKINFOLD THICKNESS; STRATUM CORNEUM;

EID: 79953180580     PISSN: 20927355     EISSN: 20927363     Source Type: Journal    
DOI: 10.4168/aair.2011.3.2.96     Document Type: Article

References (25)

1. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006;54:1-15.
2. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000;142:931-6.
3. Fukaya M. Why do patients with atopic dermatitis refuse to apply topical corticosteroids? Dermatology 2000;201:242-5.
4. Sheu HM, Lee JY, Chai CY, Kuo KW. Depletion of stratum corneum intercellular lipid lamellae and barrier function abnormalities after long-term topical corticosteroids. Br J Dermatol 1997;136:884-90.
5. Kao JS, Fluhr JW, Man MQ, Fowler AJ, Hachem JP, Crumrine D, Ahn SK, Brown BE, Elias PM, Feingold KR. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol 2003;120:456-64.
6. Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol 2008;121:1337-43.
7. Proksch E. The role of emollients in the management of diseases with chronic dry skin. Skin Pharmacol Physiol 2008;21:75-80.
8. Lee SH, Jeong SK, Ahn SK. An update of the defensive barrier function of skin. Yonsei Med J 2006;47:293-306.
9. Elias PM. Skin barrier function. Curr Allergy Asthma Rep 2008;8:299-305.
10. Mao-Qiang M, Feingold KR, Thornfeldt CR, Elias PM. Optimization of physiological lipid mixtures for barrier repair. J Invest Dermatol 1996;106:1096-101.
11. Park BD, Youm JK, Jeong SK, Choi EH, Ahn SK, Lee SH. The characterization of molecular organization of multilamellar emulsions containing pseudoceramide and type III synthetic ceramide. J Invest Dermatol 2003;121:794-801.
12. Rim JH, Jo SJ, Park JY, Park BD, Youn JI. Electrical measurement of moisturizing effect on skin hydration and barrier function in psoriasis patients. Clin Exp Dermatol 2005;30:409-13.
13. Draelos ZD. The effect of ceramide-containing skin care products on eczema resolution duration. Cutis 2008;81:87-91.
14. Ahn SK, Bak HN, Park BD, Kim YH, Youm JK, Choi EH, Hong SP, Lee SH. Effects of a multilamellar emulsion on glucocorticoid-induced epidermal atrophy and barrier impairment. J Dermatol 2006;33:80-90.
15. Beattie PE, Lewis-Jones MS. Parental knowledge of topical therapies in the treatment of childhood atopic dermatitis. Clin Exp Dermatol 2003;28:549-53.
16. Korting HC, Unholzer A, Schafer-Korting M, Tausch I, Gassmueller J, Nietsch KH. Different skin thinning potential of equipotent medium-strength glucocorticoids. Skin Pharmacol Appl Skin Physiol 2002;15:85-91.
17. Tharp MD. A comparison of twice-daily and once-daily administration of fluticasone propionate cream, 0.05%, in the treatment of eczema. Cutis 1996;57:19-26.
18. Kaidbey K, Kopper SC, Sefton J, Gibson JR. A pilot study to determine the effect of tazarotene gel 0.1% on steroid-induced epidermal atrophy. Int J Dermatol 2001;40:468-71.
19. Sheu HM, Lee JY, Kuo KW, Tsai JC. Permeability barrier abnormality of hairless mouse epidermis after topical corticosteroid: characterization of stratum corneum lipids by ruthenium tetroxide staining and high-performance thin-layer chromatography. J Dermatol 1998;25:281-9.
20. Elias PM. Stratum corneum defensive functions: an integrated view. J Invest Dermatol 2005;125:183-200.
21. Abramovits W. Atopic dermatitis. J Am Acad Dermatol 2005;53:S86-93.
22. Elias PM, Schmuth M. Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. Curr Opin Allergy Clin Immunol 2009;9:437-46.
23. Demerjian M, Choi EH, Man MQ, Chang S, Elias PM, Feingold KR. Activators of PPARs and LXR decrease the adverse effects of exogenous glucocorticoids on the epidermis. Exp Dermatol 2009;18:643-9.
24. Schmuth M, Jiang YJ, Dubrac S, Elias PM, Feingold KR. Thematic review series: skin lipids. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology. J Lipid Res 2008;49:499-509.
25. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 2005;67:15-9.